Priority Research Papers:
Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine
Metrics: PDF 1114 views | HTML 1529 views | ?
Erika Maria Parasido1,2, Alessandra Silvestri1, Vincenzo Canzonieri3, Claudio Belluco4, Maria Grazia Diodoro5, Massimo Milione6, Flavia Melotti6, Ruggero De Maria7, Lance Liotta1, Emanuel F. Petricoin1,* and Mariaelena Pierobon1,*
1 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
2 Department of Experimental Oncology, CRO-National Cancer Institute, Aviano, Italy
3 Department of Pathology, CRO-National Cancer Institute, Aviano, Italy
4 Department of Surgical Oncology, CRO-National Cancer Institute, Aviano, Italy
5 Department of Pathology, Istituto Nazionale Tumori Regina Elena, Roma, Italy
6 Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
7 Department of Pathology, Sacred Heart Catholic University of Rome, Roma, Italy
* These authors have contributed equally to this work
Mariaelena Pierobon, email:
Keywords: intra-tumor heterogeneity, personalized therapy, kinase signaling, laser capture microdissection, reverse phase protein microarray
Received: August 16, 2016 Accepted: December 09, 2016 Published: December 15, 2016
Introduction: Recent studies indicated tumors may be comprised of heterogeneous molecular subtypes and incongruent molecular portraits may emerge if different areas of the tumor are sampled. This study explored the impact of intra-tumoral heterogeneity in terms of activation/phosphorylation of FDA approved drug targets and downstream kinase substrates.
Material and methods: Two independent sets of liver metastases from colorectal cancer were used to evaluate protein kinase-driven signaling networks within different areas using laser capture microdissection and reverse phase protein array.
Results: Unsupervised hierarchical clustering analysis indicated that the signaling architecture and activation of the MAPK and AKT-mTOR pathways were consistently maintained within different regions of the same biopsy. Intra-patient variability of the MAPK and AKT-mTOR pathway were <1.06 fold change, while inter-patients variability reached fold change values of 5.01.
Conclusions: Protein pathway activation mapping of enriched tumor cells obtained from different regions of the same tumor indicated consistency and robustness independent of the region sampled. This suggests a dominant protein pathway network may be activated in a high percentage of the tumor cell population. Given the genomic intra-tumoral variability, our data suggest that protein/phosphoprotein signaling measurements should be integrated with genomic analysis for precision medicine based analysis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.